Previous Close | 1.6700 |
Open | 1.6600 |
Bid | 1.5100 x 300 |
Ask | 1.5700 x 300 |
Day's Range | 1.5000 - 1.7200 |
52 Week Range | 0.6500 - 2.1200 |
Volume | |
Avg. Volume | 353,122 |
Market Cap | 114.323M |
Beta (5Y Monthly) | 2.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5300 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.50 |
Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Victor Chong, M.D., MBA Victor Chong, M.D., MBA was appointed as Chief Medical Officer for Clearside Biomedical. ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced to
Clearside Biomedical ( NASDAQ:CLSD ) Full Year 2023 Results Key Financial Results Revenue: US$8.23m (up by US$6.90m...
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript March 13, 2024 Clearside Biomedical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Clearside Biomedical Q4 2023 Financial Results and Corporate Update Call. At this […]